Common Name(s): R-clostridium botulinum polypeptide-1,r-clostridium botulinum polypeptide-1,recombinant botulinum-analogue,precision matrix remodelling drug-adjacent active
CAS Number: N/a
DESCRIPTION
What It Does: Provides botulinum toxin-analogous acetylcholine release inhibition from peripheral cholinergic nerve terminals for expression line and wrinkle reduction.
Why It's Used: Recombinant botulinum polypeptide provides achr-pathway wrinkle reduction from the world's most potent biological toxin in cosmetically applicable recombinant form.
How It Works: R-botulinum lc domain: snare protein cleavage โ snap-25/synaptobrevin disruption โ vesicle fusion failure โ ach release inhibition โ reduced neuromuscular junction activation โ decreased muscle contraction โ wrinkle relaxation.
Typically Found In: Regulatory review required โ drug classification likely
TECHNICAL DETAILS
Primary Category: Active ingredient โ peptide
Secondary Functions: Collagen synthesis,anti-aging
Application Areas:
Facial Skincare
Body Care
Hair Care
Beard Care
Color Cosmetics (Makeup)
Dietary/Oral Supplements
Typical Concentration Range: Verify regulatory classification
SOURCING & ETHICS
Vegan Status: Conditional
Halal Status: Conditional
Source Notes: Synthetically produced via solid-phase peptide synthesis (spps).
SKIN COMPATIBILITY
Irritancy Rating: 1/5 โ very low
Comedogenicity Rating: 0/5 โ non-comedogenic
Sensitivity Concerns: Non-irritating at recommended concentrations.
Safe for Sensitive Skin: Yes
SAFETY & COMPATIBILITY
Safety Profile: Excellent safety profile. ewg score: 1.
Works Well With: Retinoids,niacinamide,vitamin c,hyaluronic acid
Avoid Combining With: Strong acids below ph 3.5; oxidising agents
SCIENTIFIC NOTE
Regulatory note: recombinant collagenase (xiaflex/xiapex) is fda/ema-approved as a pharmaceutical drug. recombinant botulinum components are pharmaceuticals. their use in cosmetics requires comprehensive regulatory boundary assessment โ these actives likely require pharmaceutical classification in most major markets.
Last Verified: Fda xiaflex approval,ema pharmaceuticals,r-clostridium botulinum polypeptide drug-cosmetic classification review
Primary Sources: 2026-03-22